These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 19768640)

  • 21. A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management.
    Louis R; Joos G; Michils A; Vandenhoven G
    Int J Clin Pract; 2009 Oct; 63(10):1479-88. PubMed ID: 19769705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial.
    Patel M; Pilcher J; Pritchard A; Perrin K; Travers J; Shaw D; Holt S; Harwood M; Black P; Weatherall M; Beasley R;
    Lancet Respir Med; 2013 Mar; 1(1):32-42. PubMed ID: 24321802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Do asthmatic smokers benefit as much as non-smokers on budesonide/formoterol maintenance and reliever therapy? Results of an open label study.
    van Schayck OC; Haughney J; Aubier M; Selroos O; Ekström T; Ostinelli J; Buhl R
    Respir Med; 2012 Feb; 106(2):189-96. PubMed ID: 22119455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice.
    Andersson F; Kjellman M; Forsberg G; Möller C; Arheden L
    Ann Allergy Asthma Immunol; 2001 May; 86(5):537-44. PubMed ID: 11379805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of early intervention with once-daily budesonide in children with mild persistent asthma: results from the START study.
    Weiss K; Buxton M; Andersson FL; Lamm CJ; Liljas B; Sullivan SD
    Pediatr Allergy Immunol; 2006 May; 17 Suppl 17():21-7. PubMed ID: 16573705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Improving asthma control in patients suboptimally controlled on inhaled steroids and long-acting beta2-agonists: addition of montelukast in an open-label pilot study.
    Dupont L; Potvin E; Korn D; Lachman A; Dramaix M; Gusman J; Peché R;
    Curr Med Res Opin; 2005 Jun; 21(6):863-9. PubMed ID: 15969886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination inhalers containing inhaled corticosteroids and long-acting beta2-agonists: improved clinical efficacy and dosing options in patients with asthma.
    Ankerst J
    J Asthma; 2005 Nov; 42(9):715-24. PubMed ID: 16316864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma.
    Sullivan SD; Buxton M; Andersson LF; Lamm CJ; Liljas B; Chen YZ; Pauwels RA; Weiss KB
    J Allergy Clin Immunol; 2003 Dec; 112(6):1229-36. PubMed ID: 14657888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between previous health care use and initiation of inhaled corticosteroid and long-acting beta2-adrenergic agonist combination therapy among US patients with asthma.
    Blanchette CM; Culler SD; Ershoff D; Gutierrez B
    Clin Ther; 2009 Nov; 31(11):2574-83. PubMed ID: 20110003
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid monotherapy.
    Hozawa S; Terada M; Hozawa M
    Pulm Pharmacol Ther; 2014 Apr; 27(2):190-6. PubMed ID: 24388868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population.
    Ye X; Gutierrez B; Zarotsky V; Nelson M; Blanchette CM
    Curr Med Res Opin; 2009 Sep; 25(9):2251-8. PubMed ID: 19622006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma.
    Tal A; Simon G; Vermeulen JH; Petru V; Cobos N; Everard ML; de Boeck K
    Pediatr Pulmonol; 2002 Nov; 34(5):342-50. PubMed ID: 12357478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy.
    Buhl R; Kuna P; Peters MJ; Andersson TL; Naya IP; Peterson S; Rabe KF
    Respir Res; 2012 Jul; 13(1):59. PubMed ID: 22816878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma.
    Sears MR; Boulet LP; Laviolette M; Fitzgerald JM; Bai TR; Kaplan A; Smiljanic-Georgijev N; Lee JS
    Eur Respir J; 2008 May; 31(5):982-9. PubMed ID: 18216054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An economic evaluation of adjustable and fixed dosing with budesonide/formoterol via a single inhaler in asthma patients: the ASSURE study.
    Price D; Haughney J; Lloyd A; Hutchinson J; Plumb J
    Curr Med Res Opin; 2004 Oct; 20(10):1671-9. PubMed ID: 15462701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma.
    Humbert M; Andersson TL; Buhl R
    Allergy; 2008 Dec; 63(12):1567-80. PubMed ID: 19032229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness and safety of adjustable maintenance dosing with budesonide/formoterol turbuhaler compared with traditional fixed doses in bronchial asthma: a multi-centre Nigerian study.
    Ige OM; Ohaju-Obodo JO; Chukwu C; Peters EJ; Okpapi J; Chukwuka C
    Afr J Med Med Sci; 2010 Sep; 39(3):165-72. PubMed ID: 21416785
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Budesonide/formoterol maintenance and reliever therapy: an effective and easy approach to asthma management].
    Mungan D
    Tuberk Toraks; 2009; 57(1):93-108. PubMed ID: 19533446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler.
    Chervinsky P; Baker J; Bensch G; Parasuraman B; Boggs R; Martin P; O'Dowd L
    Ann Allergy Asthma Immunol; 2008 Nov; 101(5):463-73. PubMed ID: 19055199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial.
    Hardy J; Baggott C; Fingleton J; Reddel HK; Hancox RJ; Harwood M; Corin A; Sparks J; Hall D; Sabbagh D; Mane S; Vohlidkova A; Martindale J; Williams M; Shirtcliffe P; Holliday M; Weatherall M; Beasley R;
    Lancet; 2019 Sep; 394(10202):919-928. PubMed ID: 31451207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.